Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bristol Myers Squibb's RayzeBio unit will pay up to $1.35 billion to license a prostate cancer radioligand therapy from Swiss biotech Philochem, the company…
Bristol Myers Squibb's RayzeBio unit said on Monday it would license a prostate cancer radioligand therapy from Swiss biotech Philochem in a deal worth up to…
Bristol Myers Squibb's radiopharmaceuticals subsidiary RayzeBio is licensing global rights to Philochem's OncoACP3, designed for both diagnostic imaging and…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
BMS's RayzeBio unit licensed global rights to Philochem's OncoACP3, a small-molecule ligand targeting acid phosphatase 3 (ACP3) for radioligand therapy and imaging of prostate cancer, for $350M upfront and up to $1B in development, regulatory and commercial milestones plus mid-single to low double-digit royalties on global net sales. Differentiated from PSMA-targeting Pluvicto. The deal closed on August 18, 2025 following U.S. FTC clearance under the Hart-Scott-Rodino Antitrust Improvements Act; RayzeBio leads development and any commercialization. A Phase I 68Ga-OncoACP3 imaging study (NCT06840535) reached primary completion in late 2025, with an Actinium-225 therapeutic variant (225Ac-OncoACP3) advancing toward clinical testing in 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Philochem AG (this deal) | 2025 | $1.4B | — |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2025 deals · Bristol-Myers Squibb Company deals · Oncology deals